Is USANA Health Sciences, Inc. overvalued or undervalued?

Jun 29 2025 11:41 AM IST
share
Share Via
As of June 27, 2025, USANA Health Sciences, Inc. is fairly valued with a P/E ratio of 16, an EV to EBITDA of 4.61, and a ROCE of 15.36%, lagging behind the S&P 500 with a year-to-date return of -13.26%.
As of 27 June 2025, the valuation grade for USANA Health Sciences, Inc. has moved from attractive to fair. The company appears to be fairly valued at this time. Key ratios include a P/E ratio of 16, an EV to EBITDA of 4.61, and a ROCE of 15.36%.
In comparison to peers, USANA's P/E ratio is lower than Nature's Sunshine Products, Inc. at 26.71, but higher than LifeVantage Corp. at 17.47. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -13.26% compared to the index's 4.96%. Overall, USANA Health Sciences, Inc. is currently fairly valued within its industry context.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News